Phenotypic Precision Medicine in Advanced Prostate Cancer
Advertisement
Latest News
Video Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Advertisement
Advertisement
Trending
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.